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Abstract
Despite remarkable advances in the therapy and prevention of prostate cancer it is still the second cause of death from
cancer in industrialized countries. Many therapies initially shown to be beneficial for the patients were abandoned due to
the high drug resistance and the evolution rate of the tumors. One of the prospective therapeutical agents even used in the
first stage clinical trials, 1,25-dihydroxyvitamin D3, was shown to be either unpredictable or inefficient in many cases. We
have already shown that TRPV6 calcium channel, which is the direct target of 1,25-dihydroxyvitamin D3 receptor, positively
controls prostate cancer proliferation and apoptosis resistance (Lehen’kyi et al., Oncogene, 2007). However, how the known
1,25-dihydroxyvitamin D3 antiproliferative effects may be compatible with the upregulation of pro-oncogenic TRPV6
channel remains a mystery. Here we demonstrate that in low steroid conditions 1,25-dihydroxyvitamin D3 upregulates the
expression of TRPV6, enchances the proliferation by increasing the number of cells entering into S-phase. We show that
these pro-proliferative effects of 1,25-dihydroxyvitamin D3 are directly mediated via the overexpression of TRPV6 channel
which increases calcium uptake into LNCaP cells. The apoptosis resistance of androgen-dependent LNCaP cells conferred by
TRPV6 channel is drastically inversed when 1,25-dihydroxyvitamin D3 effects were combined with the successful TRPV6
knockdown. In addition, the use of androgen-deficient DU-145 and androgen-insensitive LNCaP C4-2 cell lines allowed to
suggest that the ability of 1,25-dihydroxyvitamin D3 to induce the expression of TRPV6 channel is a crucial determinant of
the success or failure of 1,25-dihydroxyvitamin D3-based therapies.
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Introduction
Prostate cancer remains the most common noncutaneous
human malignancy and the second most lethal tumor among
men with the highest incidence in industrialized countries [1]. The
androgen receptor and other steroids regulate vital aspects of
prostate cellular growth and function including proliferation,
differentiation, apoptosis, lipid metabolism, and secretory action
[2]. Androgen suppression has been the leading treatment and
currently the most successful [3]. However, prostate carcinomas
eventually become androgen-irresponsive, and the cancer is
refractory to hormonal therapy — the most important reason
for prostate cancer mortality [4].
Different nuclear receptors have been targeted for therapy and
among them 1,25-dihydroxyvitamin D3 which exerts a multitude
of anti-tumor activities against cultured prostate cancer cells and
xenografts [5]. Normal and malignant prostatic epithelial cells
express vitamin D3 receptor (VDR), and activation of VDR by
1,25-dihydroxyvitamin D3 generally results in inhibition of
proliferation and cell cycle arrest [6]. However, to prevent or
treat prostate cancer, the interactions of other nuclear receptors
and signaling pathway need to be considered [7].
The function of ion channels has been discussed in relation to
proliferation and apoptosis. More recently, store operated Ca2+
channels and the Ca2+ pool in the endoplasmatic reticulum have
also been related to prostate cancer development [8]. Proliferation
of the prostate cancer cell lines LNCaP and PC3 was inhibited by
TH-1177, a substance which blocks Ca2+ entry [9]. Alterations in
Ca2+ pool and cytosolic Ca2+ have not only been described to
increase proliferation and sarcoendoplasmatic Ca2+-ATPase
(SERCA) expression in LNCaP cells [10], but also to induce
apoptosis [11]. Thus, Ca2+ homeostasis is critically involved in
cancer development and progression.
Our attention has been drawn by the observation that a
transient receptor potential highly Ca2+-selective channel subfam-
ily V member 6, TRPV6 is strongly expressed in advanced
prostate cancer and significantly correlates with the Gleason .7
grading representing a strong marker of tumor progression and
subsequent invasion into the healthy tissues [12,13]. We have
previously shown that TRPV6 forms highly calcium selective
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channels in prostate cells, whose current amplitude and inactiva-
tion behavior are tightly regulated by the intracellular calcium
concentration [10,14]. Besides we have already shown that
TRPV6 channel is involved in the control of prostate cancer
proliferation and apoptosis resistance [15]. However, the precise
role of TRPV6 in prostate pathophysiology remains illusive, and
its regulation by androgen – contradictive [16]. Moreover, VDR
being a direct activator of trpv6 promoter [17], and 1,25-
dihydroxyvitamin D3 a widely used anticancer treatment have
completed an intriguing hypothesis for TRPV6 regulation and
significance in prostate cancer. Our studies were based on the fact
that 1,25-dihydroxyvitamin D3, already used in the first stage of
clinical trials was shown to be either unpredictable or inefficient in
many cases, and the fact that TRPV6 which positively controls
prostate cancer proliferation and apoptosis resistance [15] is a
direct target of 1,25-dihydroxyvitamin D3 [17]. The question how
the known 1,25-dihydroxyvitamin D3 antiproliferative effects may
be compatible with the upregulation of pro-oncogenic TRPV6
channel was the aim of our study.
Materials and Methods
Cell culture
Human LNCaP (lymph node cancer of the prostate), LNCaP
C4-2, and DU-145 cell lines were obtained from American Type
Culture Collection (ATCC) and cultured in RPMI medium
(Gibco-BRL, CergyPontoise, France) supplemented with 10 or 2%
foetal calf serum (FCS) and containing kanamycin (100 mg/ml)
and L-glutamine (2 mM). Cells were cultured at 37uC in a
humidified atmosphere with 5% CO2 in air. The medium was
changed three times a week and cultures were split by treating the
cells with 0.25% trypsin (in PBS) for 5 min at 37uC before
reaching confluency. For the experiments, cells were seeded in 6-
well plates for PCR and western-blotting and onto glass coverslips
for immunocytochemistry and calcium imaging. For the 1,25-
dihydroxyvitamin D3 studies cells were treated with EtOH as a
control for 1,25-dihydroxyvitamin D3. Charcoal-striped foetal calf
serum (2%) was added to phenol red free RPMI medium together
with kanamycin and L-glutamin as above to incubate the cells to
create steroid-deprived conditions.
RT- PCR
Total RNA was isolated using the guanidium thiocyanate-phenol-
chloroform extraction procedure. After DNase I (Life Technologies)
treatment to eliminate genomic DNA, 2 mg of total RNA was reverse
transcribed into cDNA at 42uC using random hexamer primers
(Perkin Elmer) and MuLV reverse transcriptase (Perkin Elmer) in a
40 ml final volume, followed by real time quantitative PCR.
Quantitative real-time PCR
Quantitative real-time PCR of TRPV6 and HPRT mRNA
transcripts was done using MESA GREEN qPCR MasterMix Plus
for SYBR Assay (Eurogentec, France) on the Biorad CFX96 Real-
Time PCR Detection System. The sequences of primers are
indicated in Table 1. The HPRT gene was used as an endogenous
control to normalize variations in RNA extractions, the degree of
RNA degradation, and variability in RT efficiency. To quantify
the results we used the comparative threshold cycle method
DDC(t).
Western-blotting
Semiconfluent LNCaP cells were treated with an ice-cold lysis
buffer containing: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl,
10 mM MgCl, 1 mM PMSF, 1% Nonidet P-40, and protease
inhibitor cocktail from Sigma. The lysates were centrifuged
15,0006 g at 4uC for 20 minutes, mixed with a sample buffer
containing: 125 mM Tris-HCl pH 6.8, 4% SDS, 5% b-mercap-
toethanol, 20% glycerol, 0.01% bromphenol blue, and boiled for
5 min at 95uC. Total protein samples were subjected to 8, 10, and
15% SDS-PAGE and transferred to a nitrocellulose membrane by
semi-dry Western blotting (Bio-Rad Laboratories). The membrane
was blocked in a 5% milk containing TNT buffer (Tris-HCl,
pH 7.5, 140 mM NaCl, and 0.05% Tween 20) overnight then
probed using specific rabit polyclonal anti TRPV6 antibody
(Alomone Labs Ltd., 1/200), anti-PCNA (Santa-Cruz, 1/1000),
anti-b-actin (Lab Vision Co., 1/1000) antibodies. The bands on
the membrane were visualized using enhanced chemiluminescence
method (Pierce Biotechnologies Inc.). Densitometric analysis was
performed using a Bio-Rad image acquisition system (Bio-Rad
Laboratories).
Immunocytochemistry
The cells grown on the glass coverslips were washed once with
PBS and, if appropriate, incubated with Cholera toxin subunit B
Alexa FluorH 488 conjugate (Molecular Probes, 1/2000) for
15 min, then washed once with PBS and fixed in 3.5%
paraformaldehyde in PBS. PBS-glycine (30 mM) was used to
quench the reaction with the subsequent permeabilization with
0.1% Triton X-100. The cells were washed again in PBS and
subjected to conventional immunostaining procedure. Alexa
FluorH 546 goat anti-rabbit IgG (Molecular Probes, 1/4000) was
used as a secondary antibody for TRPV6 staining. Fluorescence
analysis was carried out using Carl Zeiss Laser Scanning Systems
LSM 510 connected to a Zeiss Axiovert 200 M with 6361.4
numerical aperture oil immersion lens at room temperature. Both
channels were excited, collected separately and then merged using
software Carl Zeiss LSM Image Examiner.
Table 1. Primers and siRNA.
No Name, Accession
Forward
(59-…- 39)
Backward
(59-…- 39) Expected Size (b.p)
1. TRPV6, NM_018646 TTGGCAGCTAGAAGGAGAGG TCTGCAGATGGTTCCAGAGA 106
2. HPRT, (NM_000194) GGCGTCGTGATTAGTGATGAT CGAGCAAGACGTTCAGTCCT 134
3. TRPV6
siRNA
59-CCUGCUGCAGCAGAAGAGG(dTdT)-39
4. TRPV6
siRNA-1
59-GACTCTCTATGACCTCACA(dTdT)-39
5. AR, siRNA 59-GACUCAGCUGCCCCAUCCA(dTdT)-39
doi:10.1371/journal.pone.0016856.t001
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Cell proliferation
Cell proliferation was measured using the CellTiter 96 Aqueous
One Solution cell proliferation assay (Promega, Madison, WI), on
the basis of the cellular conversion of the colorimetric reagent
MTS [3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium salt] into soluble formazan by
dehydrogenase enzymes found only in metabolically active,
proliferating cells. Following each treatment, 20 ml of dye solution
was added into each well in 96-well plate and incubated for 2 h.
Subsequently, absorbance was recorded at 490 nm wavelength
using an ELISA plate reader (Molecular Devices, Sunnyvale, CA).
Cellular proliferation inhibition rate is calculated as: (Acontrol-
Asample)/(Acontrol-Ablank)6100%.
Cell cycle and apoptosis assays
Flow cytometry assays were performed on cell populations
cultured in triplicate 25-cm2 flasks as originally described [18].
Approximately 106 cells were fixed with 1 ml ice-cold 70%
methanol for 30 min. After fixing, cells were pelleted by
centrifugation to remove the fixatives, washed three times with
phosphate-buffered saline (PBS) at 4uC, resuspended in 100 ml
PBS, treated with 100 ml RNAse A (1 mg/ml, Sigma), and stained
with propidium iodide (PI, Sigma) at a final concentration of
50 mg/ml. The stained cells were stored at 4uC in the dark and
analyzed within 2 h. The stained samples were measured on a
FACScan flow cytometer (Becton–Dickinson, San Jose, CA). Data
were acquired for 7000 events with a variation coefficient of less
than 5%, and red fluorescence was measured using a fluorescence
detector 3 (FL3) on the X-axis. The data were stored and analyzed
using CellQuest software to assess cell-cycle distribution patterns
(subG1 (apoptotic), G0/G1, S, and G2/M phases).
Calcium Imaging
Cells were plated onto glass coverslips and were loaded with
4 mM Fura-2 AM at room temperature for 45 min in the growth
medium. Recordings were performed in HBSS containing (in
mM): 140 NaCl, 5 KCl, 2 MgCl2, 0.3 Na2HPO3, 0.4 KH2PO4, 4
NaHCO3, 5 glucose and 10 HEPES adjusted to pH 7.4 with
NaOH. CaCl2 was adjusted to 0.07 mM or 1,8 mM depending on
the experiment. The coverslips were then placed in a perfusion
chamber on the stage of the microscope. Fluorescence images of
the cells were recorded with a video image analysis system
(Quanticell). The Fura-2 fluorescence, at the emission wavelength
of 510 nm, was recorded by exciting the probe alternatively at 340
and 380 nm. The signal ratio at 340/380 nm was converted into
[Ca2+]i level using an in vitro calibration.
siRNA cell transfection
LNCaP cells were transfected overnight with 200 nM of siRNA-
TRPV6 1 and 2 per well of a six-well plate using ‘‘Gene porter 2’’
(Gene Therapy Systems, Inc.) in a final volume of 1 ml. Ready-to-
use siRNA-TRPV6s (processing option:A4) were synthesized by
Dharmacon Research Inc (Lafayette, USA)(see Table 1).
Reagents
All reagents were purchased from Sigma (Sigma, L’Isle d’Abeau
Chesnes, France) unless otherwise specified.
Statistics
Data were expressed as mean6SD. Statistical analysis were
carried out using Student’s unpaired t-tests. * - P,0.05 or ** - P,
0.01 indicate statistical significance.
Results
The effect of 1,25-dihydroxyvitamin D3 on prostate cancer cell
proliferation has been studied in two experimental conditions: 2%
and 10% foetal calf serum (FCS)-supplemented RPMI medium.
The growth of androgen-dependent LNCaP cell line was
surprisingly increased by 100 nM 1,25-dihydroxyvitamin D3 in
2% FCS supplemented medium and suppressed in 10% FCS
(Fig. 1A). We have already demonstrated the role of TRPV6
channel in proliferation of prostate cancer cells [15], and therefore
we sought to investigate the regulation of TRPV6 channel
expression by 1,25-dihydroxyvitamin D3. Since it has been shown
that trpv6 is a VDR-regulated gene [17], we have studied the
regulation of TRPV6 expression by 1,25-dihydroxyvitamin D3 in
LNCaP cells in different steroid content of the media (Fig. 1B, C).
1,25-dihydroxyvitamin D3 appears to directly activate the trpv6
gene in LNCaP cells, though in 10% FCS medium its effects were
not that significant (Fig. 1B) than in 2% FCS (Fig. 1C). 1,25-
dihydroxyvitamin D3 significantly dose-dependently increased
TRPV6 mRNA expression in 2% FCS-containing RPMI medium
(Fig. 1C). To check whether the diminished effects of 1,25-
dihydroxyvitamin D3 were due to FCS content and not to the
optimal effect time we performed the time curve using the
maximal concentration of 100 nM over three days at different
time intervals (Fig. 1D). To confirm the significant induction of
TRPV6 protein by 1,25-dihydroxyvitamin D3 in 2% FCS
containing RPMI medium obtained by real time quantitative
PCR a western-blotting was performed. It showed a considerable
increase in TRPV6 protein level upon activation with 100 nM
1,25-dihydroxyvitamin D3 (Fig. 1E). Immunocytochemistry using
TRPV6 specific antibody showed the expression of TRPV6
channels in LNCaP cells (Fig. 1F) as well as its localisation on the
plasma membrane using Cholera toxin (CTX) conjugated with
FITC labelling specifically G2M lipids in the membrane. Hence,
the effects of 1,25-dihydroxyvitamin D3 on the growth of
androgen-dependent LNCaP cells depend on the relative steroid
content. Besides, 1,25-dihydroxyvitamin D3 significantly increases
the expression of TRPV6 channel in low-steroid conditions.
TRPV6 is involved in1,25-dihydroxyvitamin D3-induced
proliferation of LNCaP cells
According to the data obtained above the effects of 1,25-
dihydroxyvitamin D3 in 2% FCS were further studied. Since we
have already demonstrated the role of TRPV6 channel in
proliferation of prostate cancer cells [15], and knowing that there
is no chemical compound available so far to selectively block
TRPV6, we used siRNA approach to selectively knockdown
TRPV6. Three different methodological approaches were em-
ployed to assess proliferation of LNCaP cells in 2% FCS-
containing medium (Fig. 2A–C). The number of viable prolifer-
ating cells was measured by MTS assay. siRNA-TRPV6
significantly decreased the number of proliferating cells from day
2 to 4 after transfection (D0) (Fig. 2A). 100 nM 1,25-dihydrox-
yvitamin D3 was able to increase proliferation of LNCaP cells
whereas TRPV6 knockdown inversed this stimulation to the level
even lower than in control. siRNA against androgen receptor
(AR), known to be crucial for prostate growth and development,
was used as a positive control to achieve strong and reliable effects
on prostate cell viability.
A cell cycle assay using propidium iodide staining was
performed to precise the effects of TRPV6 knockdown as well as
1,25-dihydroxyvitamin D3 effects and the role of TRPV6 therein,
on cell cycle phase distribution of LNCaP cells cultured in 2%
FCS containing RPMI medium (Fig. 2B). Indeed, we confirmed
Vitamin D3 Action via TRPV6 on the Prostate Cancer
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16856
Figure 1. The effects of 1,25-dihydroxyvitamin D3 on proliferation of LNCaP cells and expression of TRPV6 channel. A, 1,25-
dihydroxyvitamin D3 effects on proliferation rate measured by MTS assay of LNCaP cells incubated either with 2% or 10% FCS-containing RPMI
medium, * - P,0.05, ** - P,0.01, as compared to their respective controls (DMSO), n = 3. B, The upregulation of TRPV6 mRNA expression by 1,25-
dihydroxyvitamin D3 in LNCaP cells cultured in 10% FCS-containing RPMI medium; * - P,0.05, as compared to control (DMSO), n = 3. C, The
upregulation of TRPV6 mRNA expression by 1,25-dihydroxyvitamin D3 in LNCaP cells cultured in 2% FCS-containing RPMI medium; * - P,0.05, ** - P,
0.01, as compared to control (DMSO), n = 3. D, The time-dependence of TRPV6 expression under 100 mM 1,25-dihydroxyvitamin D3 treatment in
LNCaP cells incubated in 10% FCS-containing RPMI medium. * - P,0.05, ** - P,0.01, as compared to control (DMSO), n = 3. E, a western-blotting of
TRPV6 protein levels induced by 1,25-dihydroxyvitamin D3 treatment for 3 days in LNCaP cells incubated in 2% FCS-containing RPMI medium. F, A
confocal microscopy showing the pattern of TRPV6 protein expression and localisation onto the plasma membrane of LNCaP cells cultivated in 2%
FCS-containing RPMI medium. Cholera toxin conjugated to FITC (CTX, green) used to stain the plasma membrane as well as the TRPV6 channel
(TRPV6, red), and their respective merge (CTX+TRPV6) are shown.
doi:10.1371/journal.pone.0016856.g001
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that siRNA-TRPV6 decreased the number of cells entered into the
S-phase. The percentage of the cells entered into the S-phase was
significantly higher in 100 nM 1,25-dihydroxyvitamin D3 treated
cells than in control. Pretransfection of LNCaP cells with siRNA-
TRPV6 attenuated 1,25-dihydroxyvitamin D3 increased prolifer-
ation, though not to the full extent. siRNA-AR as above was used
as a positive control and showed a considerable decrease in % of
the cells entered into the S-phase.
We also monitored a protein level of proliferating cell nuclear
antigen (PCNA) using the same conditions. PCNA appeared to be
significantly decreased upon siRNA-TRPV6 knockdown. 1,25-
dihydroxyvitamin D3-treated cells expressed 2-fold less PCNA as
was also observed by the combined treatment of siRNA-TRPV6
and 100 nM 1,25-dihydroxyvitamin D3. The level of PCNA in
siRNA-AR-treated cells was undetectable (Fig. 2C).
A cell cycle assay also allowing measuring a number of
apoptotic cells as a subG1 population was employed. 100 nM
1,25-dihydroxyvitamin D3 had no influence on apoptosis itself,
whereas siRNA-TRPV6 had significant effect on apoptosis rate
(Fig. 2D). However, combining the treatment of 100 nM 1,25-
dihydroxyvitamin D3 with the transfection of siRNA-TRPV6
significantly increased the number of apoptotic cells much more
than siRNA-TRPV6 pretreatment alone (Fig. 2D). Thus, TRPV6
is involved in both proliferation and apoptosis resistance of
LNCaP cells and the effects of 1,25-dihydroxyvitamin D3 are
strongly dependent on TRPV6 expression.
TRPV6 mediates 1,25-dihydroxyvitamin D3-induced Ca2+-
uptake in LNCaP cells
In order to study the contribution of TRPV6 as a highly Ca2+-
selective channel to Ca2+-uptake in LNCaP cells, we measured
intracellular calcium levels ([Ca2+]i) in LNCaP cells cultured in 2%
FCS containing RPMI medium after consequent changes in
extracellular calcium levels ([Ca2+]o). In control cells treated with
EtOH (CTRL) the variation in [Ca2+]o produced significant
changes in [Ca2+]i (Fig. 3A). siRNA-TRPV6 knockdown de-
creased the amplitude of 2 mM [Ca2+]o-evoked increase in [Ca
2+]i
(Fig. 3A and C). 100 nM 1,25-dihydroxyvitamin D3 increased by
itself basal [Ca2+]i significantly as well as increased [Ca
2+]i
response on application of 2 mM [Ca2+]o which was completely
reversed by the pretreatment with siRNA-TRPV6 (Fig. 3C). These
data indicate that TRPV6 constitutively mediates Ca2+-uptake in
Figure 2. The effects of 1,25-dihydroxyvitamin D3 on proliferation and apoptosis resistance of LNCaP cells are mediated via TRPV6
channel. A, LNCaP cells proliferation in 2% FCS-containing RPMI medium treated with 1,25-dihydroxyvitamin D3 (100 nM, applied at D1), siRNA-
TRPV6 (siTRPV6, 80 nM, transfected at D0), the combined treatment of 1,25-dihydroxyvitamin D3 and siTRPV6 specified above, and siRNA-AR (siAR,
80 nM, transfected at D0) as a positive control. * - P,0.05, ** - P,0.01, as compared to control, n = 4; B, a cell cycle assay of LNCaP cells (incubated
with 2% FCS-containing RPMI medium) for the same conditions as in MTS assay (A) (D3 equals 100 nM 1,25-dihydroxyvitamin D3), carried out by flow
cytometry of the cells stained with propidium iodide. * - P,0.05, ** - P,0.01, 1 - P,0.05 vs. Vitamin D3; n = 3. C, a western-blotting of proliferating
cell nuclear antigen (PCNA) in the conditions indicated above as compared to b-actin. D, an apoptosis assay carried out by flow cytometry as a subG1
population of LNCaP cells cultured in 2% FCS-containing RPMI medium stained with propidium iodide. * - P,0.01 vs. control; n = 3.
doi:10.1371/journal.pone.0016856.g002
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LNCaP cells and TRPV6 also accounts for 1,25-dihydroxyvitamin
D3-mediated enhanced Ca2+-uptake.
The effects of 1,25-dihydroxyvitamin D3 on different
androgen-independent cell lines
Two different androgen-independent cell lines were used: an
androgen receptor-deficient DU-145 and androgen-insensitive
LNCaP C4-2 cell lines. Cells were cultivated in the same
conditions of 2 or 10% FCS supplemented RPMI medium and
the effects of 1,25-dihydroxyvitamin D3 were studied (Fig. 4). The
effects of 1,25-dihydroxyvitamin D3 on androgen receptor
deficient DU-145 cell line were likely to be serum-dependent
since in 2% FCS the proproliferative effects of 1,25-dihydrox-
yvitamin D3 were conserved (Fig 4A), whereas in 10% FCS its
effects were abolished (Fig. 4B). The other cell line insensitive to
steroids, but still expressing the androgen receptor, LNCaP C4-2
was used, where the effects of 1,25-dihydroxyvitamin D3 were
shown to be FCS-independent and 100 nM 1,25-dihydroxyvita-
min D3 exerted its strong anti-proliferative effects (Fig. 4C–D). A
real time quantitative PCR was performed showing the regulation
of TRPV6 expression in DU-145 cells by 100 mM 1,25-
dihydroxyvitamin D3 in both 2 and 10% FCS containing medium
(Fig. 4E). Steroid-deprived conditions in the case of LNCaP cells
(LNCaP-ST) were also used to confirm that the induction of
TRPV6 expression strongly depends on the steroid content of the
culture medium (Fig. 4F). Thus the pro-proliferative effects of
1,25-dihydroxyvitamin D3 on the growth of PCa cells are
determined by its ability to induce the expression of TRPV6
channel and its induction appears to be strongly steroid-
dependent.
Discussion
One of the most important finding of the present work is that
1,25-dihydroxyvitamin D3 may enhance proliferation of LNCaP
cells. We have clearly shown that both proliferation rate and the
number of the cells entering into the S-phase are increased upon
1,25-dihydroxyvitamin D3 treatment. These effects entirely
depend on the expression and function of TRPV6 channel which
has been previously shown to be implicated in prostate cancer
growth and apoptosis-resistance [15]. A previously reported 1,25-
dihydroxyvitamin D3 antiproliferative activity in prostate cancer
may be compromised by TRPV6 upregulation.
A number of works has already published TRPV6 induction by
1,25-dihydroxyvitamin D3 in intestine [19], kidney [20], semicir-
cular canal [21], and even prostate cancer cells [22]. Five VDR
responsive elements were found in the human gene encoding the
epithelial calcium channel TRPV6 suggesting its direct regulation
by 1,25-dihydroxyvitamin D3 via its putative receptor [17]. We
have confirmed in our cell model that the expression of TRPV6 is
directly upregulated by 1,25-dihydroxyvitamin D3 in dose- and
time-dependent fashion. Our results suggest that the nature of this
upregulation is steroid-dependent since in steroid-deprived
conditions the effects of 25-dihydroxyvitamin D3 are abolished.
This finding is consistent with the data that activities of 1,25-
Figure 3. TRPV6 is an essential Ca2+-entry channel involved in 1,25-dihydroxyvitamin D3 increased Ca2+ uptake in LNCaP cells. A,
TRPV6 involvement in Ca2+ uptake in LNCaP cells cultured in 2% FCS-containing RPMI medium and treated either with siCT (CTRL) or siRNA-TRPV6
(both 80 nM, 24 hours). B, Ca2+ uptake in LNCaP cells cultured in 2% FCS-containing RPMI medium and under 1,25-dihydroxyvitamin D3 (100 nM, 3
days) treated either with siCT (CTRL) or siRNA-TRPV6 (both 80 nM, 24 hours). C, a corresponding histogram showing relative [Ca2+]i levels after
consequent [Ca2+]o switches in the conditions as indicated above. * - P,0.05 (as compared to control); ** - P,0.01, n = 140.
doi:10.1371/journal.pone.0016856.g003
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dihydroxyvitamin D3 in LNCaP cells are dependent upon steroid
co-regulation and that, for instance, androgen receptor upregula-
tion by 1,25-dihydroxyvitamin D3 likely contributes to the
synergistic actions of 1,25-dihydroxyvitamin D3 and DHT in
these cells [23]. The data from the laboratory of Feldman show
that the addition of DHT at 1 nM to the medium restored the
antiproliferative activity of 1,25-dihydroxyvitamin D3, whereas an
antiandrogen, Casodex, completely blocked 1,25-dihydroxyvita-
min D3 antiproliferative and PSA stimulation activities when cells
were cultured in FBS medium [23].
The ability of 1,25-dihydroxyvitamin D3 to inhibit prostate
growth has been demonstrated in primary cultured cells from
normal tissues, benign prostatic hyperplasia (BPH) and prostate
cancer, and several xenograft models of prostate cancer [5],
however, no relation to TRPV6 responsiveness has been
demonstrated so far. The mechanism for 1,25-dihydroxyvitamin
D3 activity is not completely clear but relates to different activities
as to pre-receptor differences in pharmacokinetics, as well as
differences in the functional conformation of the ligand-bound
VDR complex which can alter properties of retinoid X-receptor
hybridization, DNA binding and co-activator recruitment [24].
The mechanism of growth inhibition by 1,25-dihydroxyvitamin
D3 appears to be mutifactorial but induction of p21WAF1/CIP1
and/or p27Kip1 seems to be a major pathway [25].
We are the first to report that the effects of 1,25-dihydrox-
yvitamin D3 may be pro-proliferative when mediated by the direct
induction of trpv6 gene expression in human highly cancerous
androgen-dependent LNCaP cell line. The question remains open
whether 1,25-dihydroxyvitamin D3 treatment is feasible in cancer
stages and metastasis being distinct in high TRPV6 expression, or,
otherwise, in the prostate cancer cells biopsies still responsive to
1,25-dihydroxyvitamin D3 treatment by overexpressing TRPV6.
Figure 4. The effects of 1,25-dihydroxyvitamin D3 on androgen-independent cell lines. A, B, The effects of 1,25-dihydroxyvitamin D3 on
androgen receptor-deficient DU-145 cell line in both 2 and 10% FCS-containing RPMI medium (A and B, respectively), * - P,0.05 (as compared to
control), n = 3. C, D, The effects of 1,25-dihydroxyvitamin D3 on androgen-insensitive LNCaP C4-2 cell line in both 2 and 10% FCS-containing RPMI
medium (C and D, respectively), * - P,0.05 (as compared to control), n = 3. E, the relative expression levels of TRPV6 channel in DU-145 cells treated
with 100 mM 1,25-dihydroxyvitamin D3 for 3 days in 2 and 10% FCS-containing RPMI medium, * - P,0.05 (as compared to control), n = 3. F, the
expression of TRPV6 channel induced by 100 nM 1,25-dihydroxyvitamin D3 for 3 days in LNCaP cells in steroid-deprived RPMI medium (LNCaP-ST),
n = 3.
doi:10.1371/journal.pone.0016856.g004
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Thus, 1,25-dihydroxyvitamin D3 upregulates TRPV6 which
considerably increases [Ca2+]i providing enhanced Ca
2+-uptake by
LNCaP cells. This 1,25-dihydroxyvitamin D3-induced Ca2+-
uptake dramatically increases proliferation rate and a number of
the cells entering into the S-phase and also contributes to the
enhanced apoptosis resistance. Intriguingly, the apoptosis remains
unaffected upon 1,25-dihydroxyvitamin D3 treatment which may
be explained by the responsiveness of LNCaP cell line to 1,25-
dihydroxyvitamin D3 via increasing the expression of TRPV6
channel and therefore enhancing the resistance to apoptosis.
However, when LNCaP cells are treated with 1,25-dihydroxyvi-
tamin D3 but pretransfected with siRNA-TRPV6 and thus void of
this channel they are much more subjected to apoptosis that it
becomes comparable to impact of siRNA against AR used a
positive control. This implies that the calcium supplied into the
cancer cell via TRPV6 channel is used to counteract the effects of
1,25-dihydroxyvitamin D3 which have to be antiproliferative in
the absence or low presence of this channel. We conclude that
TRPV6 is a serious determinant for 1,25-dihydroxyvitamin D3
pro- or antiproliferative activity.
Our data are not contradictory to the previously published
works and are consistent with the hypothesis that the growth
inhibitory effects of 1,25-dihydroxyvitamin D3 are partially
mediated through its ability to modulate PCNA expression [26].
A PCNA protein level being two-fold decreased upon 1,25-
dihydroxyvitamin D3 treatment is further declined in LNCaP cells
transfected with siRNA-TRPV6, with or without 1,25-dihydrox-
yvitamin D3. These conditions are characterized by the
suppression of cell proliferation, therefore suggesting a potent
contramechanism mediated by TRPV6.
1,25-dihydroxyvitamin D3 also up-regulates the expression of
androgen receptor (AR) and PSA, and both biochemical and
immunohistochemical analyses show proportionately greater
increased presence of AR in the nucleus and reduced in the
cytosol [27]. These evidences allow to suggest multivectorial
differential effects of 1,25-dihydroxyvitamin D3 on the prolifera-
tion machinery, especially in cancer. A two-fold downregulation of
a particular set of DNA replication genes including a cell division
cycle 6 homolog, a DNA polymerase alpha subunit, PCNA, two
DNA polymerase delta subunits, and flap-structure specific
endonuclease 1 [28], seems unlikely to drastically affect prolifer-
ation by itself.
On the other side, 1,25-dihydroxyvitamin D3 is known to
stimulate DNA synthesis via sequential activation of Raf and the
mitogen-activated protein kinase [29]. VDR protein was also
shown to associate with Shc, indicating that this steroid hormone is
able to signal through the transcription-independent pathways
similar to those used by peptide hormones and cytokines [29]. A
combination of 1,25-dihydroxyvitamin D3 and DHT has already
been demonstrated to increase DNA synthesis in LNCaP cells
[30], however the other works show either no significant or
inhibition of proliferation by 1,25-dihydroxyvitamin D3 alone.
Moreover, 1,25-dihydroxyvitamin D3 stimulates the proliferation
of vascular smooth muscle cells [31], epiphyseal chondrocytes
[32], myoblasts [33], skin cells [29,34], mammalian epithelial cells
[35], myeloid leukemia cell lines HL-60 and KG-1a [36], T-cells
of tumor bearers [37], chromaffin cells [38], carcinoma C-cells
[39] etc.
The genomic sequence corresponding to 6000 bp upstream and
100 bp downstream of hTRPV6 ATG has been taken for the
transcription factor analysis (data not shown). The MatInspector
7.7.3 program (Genomatix Software GmbH) has been employed
to analyse the putative steroid receptor binding sites [40]. The
hTRPV6 promoter sequence was analysed for the presence of
different steroid-responsive elements using prostate specific matrix
which is associated with transcription factors expressed and
transcriptionally active in this tissue. Numerous steroid-responsive
elements including but not limited to VDR, androgen receptor,
and glucocorticoid receptors, were found which suggests the
possible strong regulation of trpv6 gene by different steroid
receptors and therefore may represent certain temporal and
spatial limits for each particular nuclear receptor to induce the
transcription of the trpv6 gene. This latter evidence may explain
why in high level steroid conditions the expression of TRPV6
channel may be not affected or even downregulated which may
trigger the activation of a different pathway than expected.
The combined 1,25-dihydroxyvitamin D3 therapy has recently
become an advantage in treating prostate cancer. The combined
treatment with other compounds interacting directly or indirectly
with the VDR pathway like inhibitors of histone deacetylation
[41], a non-steroid anti-inflammatory drug [42], or genistein and
trichostatin A [43], will shift downstream signaling to the required
direction to achieve beneficial effects.
In conclusion, we have shown that TRPV6 is directly implicated
in 1,25-dihydroxyvitamin D3-stimulated proliferation in low
steroid conditions. The apoptosis resistance due to TRPV6
channel may be overcome by synergistic action of 1,25-
dihydroxyvitamin D3 and selective TRPV6 knockdown. 1,25-
dihydroxyvitamin D3-induction of TRPV6 expression should be
taken into account while treating TRPV6-positive/inducible
tumors. The data strongly suggest that the ability of 1,25-
dihydroxyvitamin D3 to induce the expression of TRPV6 channel
is the crucial determinant of the success or failure of 1,25-
dihydroxyvitamin D3-based therapies.
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